The tale of three pandemics



HIV/AIDS Pandemic 1980



Ebola Pandemic

2016

NIH Intramural Post-Infection ME/CFS Study



SARS CoV-2 Pandemic 2020



Ebola Pandemic 2016

Post-Ebola Syndrome

NIH Intramural Post-Infection ME/CFS Study



SARS CoV-2 Pandemic 2020

Long-COVID



Post Acute Infection Syndromes



Post Acute Infection Syndromes



Post Acute Infection Syndromes

Proposed Pathophysiology of ME/CFS





Immune Exhaustion in Long-COVID

Persistent immune exhaustion at one year



unpublished

Suggest Next Steps

- Continue analysis and publication of data/samples collected
- Reanalysis of data by other researchers
- Validation in other cohorts
- Discuss and develop plans for clinical trials
- Study pathophysiology in the context of clinical trials

Proposed Pathophysiology of ME/CFS



Therapeutic approaches for ME/CFS



Potential immunomodulatory agents for clinical trials in select ME/CFS populations

- Persistent antigen and T cell exhaustion:
 - Checkpoint inhibitors
- B cell activation (women)
 - Anti-CD20
 - Anti-CD19
 - BTK inhibitors (planned)
- T cell activation (men)
 - Mycophenylate
 - Tacrolimus
 - Jak/STAT inhibitors
- Innate immune activation
 - IL-1 blockers
 - IL-6 antagonist
 - TNF-alpha inhibitors
- Non-specific immune modulators
 - Intravenous immunoglobulin
 - Immunoadsorption (ongoing)

Patient suggested drugs

- Poly-IC
- Low dose naltrexone
- Thymosin alpha-1
- Alipripazole (Abilify)
- Supplements (nattokinase, serrapeptase or lumbrokinase)

Trial Design

- Platform
 - Multiple drugs can be studied simultaneously and compared to a single placebo arm
- Cross over study
 - All patients receive drug or placebo

Current Studies on PASC/ Long-COVID

Deep Phenotyping Study

925 inquiries: 33 patients enrolled

Intervention Studies

Intravenous Immunoglobulin

crossover placebo controlled goal: 34 patients recruited: 133 screened; 14 enrolled

Pembrolizumab (in development)

Tissue Reservoir (in scientific review)

Neuropathology Study (on going)

